The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
 
Sung Hee Lim
No Relationships to Disclose
 
Izuma Nakayama
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/UCB Japan
Research Funding - Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Min-Hee Ryu
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
 
Jong Gwang Kim
No Relationships to Disclose
 
Takeshi Omori
Speakers' Bureau - Bristol-Myers Squibb Japan; Johnson & Johnson/MedTech; Medtronic; Ono Pharmaceutical
 
Sang Cheul Oh
No Relationships to Disclose
 
Jin Young Kim
No Relationships to Disclose
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BeOne (Inst); Beringer Ingelheim (Inst); Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Jazz Pharmaceuticals (Inst); Lilly; MSD Oncology; Roche/Genentech; Sillajen
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Celltrion; Merck KGaA; MSD Oncology; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; BeiGene; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; PIN therapeutics; Takeda
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avelos Therapeutics (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IDRx (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Leap Therapeutics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Torl Biotherapeutics (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Yuhan (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Nozomu Machida
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - ALX Oncology (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Sun Jin Sym
No Relationships to Disclose
 
Yukiya Narita
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/Astra Zeneca
Speakers' Bureau - Astellas Pharma; BeOne; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Ono Pharmaceutical (Inst)
 
Young-Iee Park
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Henlius (Inst); Innovent Biologics (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Hisashi Hosaka
Research Funding - Ono Pharmaceutical
 
Beodeul Kang
No Relationships to Disclose
 
In-Ho Kim
No Relationships to Disclose
 
Li-Yuan Bai
Honoraria - Ipsen; Ono Pharmaceutical; Taiwan Society for Therapeutic Radiology and Oncology; Taiwan Society for Therapeutic Radiology and Oncology; TTY Biopharm
Consulting or Advisory Role - Amgen; Astellas Pharma
Research Funding - Eisai
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CMIC Co., Ltd.; Daiichi Sankyo; eChainaHealth,Inc.; Elevation Oncology; Elevation Oncology; Gilead Sciences; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Leap Therapeutics; Levolution Medicines,Inc.; Moderna.Inc; MSD; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Phanes Therapeutics; Sanofi; Scandion Oncology; Suzuhou Liangyihui Network Technology Co.,; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Insyte Biosciences G.K., (Inst); Medpace Japan K.K., (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)